{"doi":"10.1093/ckj/sfac189","title":"SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence","abstract":"<jats:title>ABSTRACT</jats:title>\n               <jats:p>Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a class of novel oral anti-hyperglycemic agents which are increasingly used in clinical practice. SGLT-2 inhibitors improve glycemic control and cardiorenal outcomes, promote weight loss, and reduce blood pressure. Randomized controlled trials have demonstrated that SGLT-2 inhibitors reduce proteinuria and delay progression of kidney disease in patients with albuminuria. However, whether SGLT-2 inhibitors have similar benefits in patients with nephrotic-range proteinuria has not been well established. Evidence to date has been limited to case reports, case series and secondary analyses of randomized controlled trials. This is the first comprehensive review on the effectiveness of SGLT-2 inhibitors for the treatment of patients with nephrotic-range albuminuria or proteinuria. Overall findings support a likely beneficial role of SGLT-2 inhibitors in reducing proteinuria and delaying chronic kidney disease progression in patients with nephrotic-range proteinuria.</jats:p>","journal":"Clinical Kidney Journal","year":2023,"id":631508,"datarank":0.5495342469194471,"base_score":3.6635616461296463,"endowment":3.6635616461296463,"self_citation_contribution":0.5495342469194471,"citation_network_contribution":0.0,"self_endowment_contribution":0.5495342469194471,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":38,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1636553,"name":"Ozgun E Sahin","orcid":null,"position":1,"is_corresponding":false},{"id":1080210,"name":"Sidar Copur","orcid":null,"position":2,"is_corresponding":false},{"id":1636555,"name":"Senem Danacı","orcid":null,"position":3,"is_corresponding":false},{"id":23179,"name":"Alberto Ortíz","orcid":"0000-0002-9805-9523","position":4,"is_corresponding":false},{"id":922850,"name":"Kevin Yau","orcid":"0000-0001-8653-6778","position":5,"is_corresponding":false},{"id":1636556,"name":"David Z I Cherney","orcid":null,"position":6,"is_corresponding":false},{"id":282740,"name":"Mehmet Kanbay","orcid":"0000-0002-1297-0675","position":7,"is_corresponding":false},{"id":1636552,"name":"Zeynepgul Kalay","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence","abstract":"<jats:title>ABSTRACT</jats:title>\n               <jats:p>Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a class of novel oral anti-hyperglycemic agents which are increasingly used in clinical practice. SGLT-2 inhibitors improve glycemic control and cardiorenal outcomes, promote weight loss, and reduce blood pressure. Randomized controlled trials have demonstrated that SGLT-2 inhibitors reduce proteinuria and delay progression of kidney disease in patients with albuminuria. However, whether SGLT-2 inhibitors have similar benefits in patients with nephrotic-range proteinuria has not been well established. Evidence to date has been limited to case reports, case series and secondary analyses of randomized controlled trials. This is the first comprehensive review on the effectiveness of SGLT-2 inhibitors for the treatment of patients with nephrotic-range albuminuria or proteinuria. Overall findings support a likely beneficial role of SGLT-2 inhibitors in reducing proteinuria and delaying chronic kidney disease progression in patients with nephrotic-range proteinuria.</jats:p>","is_dataset_classified":null,"base_score":3.6635616461296463,"endowment":3.6635616461296463,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36726436","pmcid":"PMC9871839","openalex_id":"https://openalex.org/W4293280727","authors":[],"funders":[{"funder_name":"Amicus","grant_id":"","title":null},{"funder_name":"Fresenius Medical Care","grant_id":"","title":null},{"funder_name":"GSK","grant_id":"","title":null},{"funder_name":"Vifor Pharma","grant_id":"","title":null},{"funder_name":"AstraZeneca","grant_id":"","title":null},{"funder_name":"Bayer","grant_id":"","title":null},{"funder_name":"Idorsia","grant_id":"","title":null},{"funder_name":"Astellas Pharma US","grant_id":"","title":null},{"funder_name":"Amgen","grant_id":"","title":null},{"funder_name":"Chiesi Farmaceutici","grant_id":"","title":null},{"funder_name":"Menarini Group","grant_id":"","title":null},{"funder_name":"Alexion","grant_id":"","title":null},{"funder_name":"Sanofi-Genzyme","grant_id":"","title":null},{"funder_name":"Advicciene","grant_id":"","title":null},{"funder_name":"Kyowa Kirin","grant_id":"","title":null},{"funder_name":"Novo-Nordisk","grant_id":"","title":null}],"total_grants":16,"fwci":4.0111,"citation_percentile":0.95350158,"influential_citations":0,"citation_trend":[{"year":2023,"count":6},{"year":2024,"count":13},{"year":2025,"count":13},{"year":2026,"count":6}],"oa_status":"gold","license":"cc-by-nc","oa_locations":[{"url":"https://academic.oup.com/ckj/advance-article-pdf/doi/10.1093/ckj/sfac189/45877227/sfac189.pdf","host_type":"journal"},{"url":"https://academic.oup.com/ckj/advance-article-pdf/doi/10.1093/ckj/sfac189/45877227/sfac189.pdf","host_type":"publisher"},{"url":"https://academic.oup.com/ckj/article-pdf/16/1/52/48843582/sfac189.pdf","host_type":"publisher"},{"url":"https://doi.org/10.1093/ckj/sfac189","host_type":"journal"},{"url":"https://unitec.researchbank.ac.nz/handle/10652/1862","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36726436","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9871839","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC9871839","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC9871839?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Diabetes Treatment and Management","Renal Diseases and Glomerulopathies","Chronic Kidney Disease and Diabetes"],"mesh_terms":[],"keywords":["Proteinuria","Albuminuria","Medicine","Nephrotic syndrome","Kidney disease","Randomized controlled trial","Internal medicine","Glycemic","Diabetes mellitus","Urology","Intensive care medicine","Kidney","Endocrinology","Diabetic nephropathy","Sglt-2 Inhibitors","Diabetic Kidney Disease","Nephrotic-range Proteinuria"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T23:47:25.750221Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}